AUTHORS
Olalekan Oluwole, MD, MPH, Yannis K. Valtis I, MD2, Jacob Ambrose, MS3, Enrico De Nigris, MSc4, Jennifer Prescott, PhD5, Razia B. Akhtar, MD6, Diana Chirovsky, PhD, MS7, Holger Keim, PhD, MBA8, Christina M Zettler, MPH9, Ming He, MD10, Mark Blaine Geyer, MD11
AFFILIATIONS
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Verana Health (formerly COTA, Inc.), New York, New York, United States
4 MSD (UK) Limited, London, United Kingdom
5 Merck & Co., Inc., Rahway, New Jersey, United States
6 Merck & Co., Inc., Rahway, New Jersey, United States
7 Merck & Co., Inc., Rahway, New Jersey, United States
8 Merck & Co., Inc., Rahway, New Jersey, United States
9 Verana Health (formerly COTA, Inc.), New York, New York, United States
10 Verana Health (formerly COTA, Inc.), New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction: Adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) have historically experienced poor long-term outcomes. Newer antigen-targeted therapies, including blinatumomab (blina), inotuzumab, and chimeric antigen receptor T-cell (CAR-T) therapy, have improved outcomes in clinical trials; however, real-world (rw) evidence are sparse.
Aim: Our study characterizes contemporary real-world treatment (tx) patterns and outcomes among adults with R/R B-ALL in the United States (US).
Methods: This retrospective, observational, cohort study used the COTA, Inc. electronic health records-based dataset, a longitudinal real-world dataset of patients (pts) treated in academic and community settings in the US. Eligible pts were diagnosed in 2018 or later with B-ALL and received at least one anti-neoplastic regimen on or before April 18, 2025 (allowing for 3 months (mos) of potential follow-up with data cutoff July 18, 2025). Pts with concurrent primary malignancies, tx initiation more than 30 days prior to diagnosis, or insufficiently precise key study dates were excluded. R/R disease was defined as documentation of: (1) progression or persistent disease/no response on or after the end of frontline induction, (2) non-maintenance regimen after maintenance tx, (3) re-induction for persistent disease (except immediately following initial induction), or (4) salvage therapy. The R/R index date was the date of initiation of tx for R/R disease, and Philadelphia chromosome (Ph) status (including Ph-like) was determined based on molecular marker results (anytime prior to index until 30 days after index), subtype, and relevant tx data. MRD status was defined using physician-stated qualitative interpretation or a quantitative MRD result (positive = ≥ 1x10-4). Rw event-free survival (rwEFS; defined as the duration of time from R/R tx initiation to subsequent documentation of progression/relapse, persistent disease/no response, or death among all pts) and overall survival (rwOS) were analyzed using the Kaplan-Meier method.
Results: Among 598 frontline-treated pts and over median follow-up of 18.7 mos (IQR: 8.2, 40.9), 161 (27%) subsequently received tx for R/R disease. Median age at R/R index date was 45 years, and pts were majority male (59%) and White (60%). The practice setting distribution was nearly even (51% community-treated and 49% academic). One-third (N=53) of R/R pts had Ph+ disease, and 67% (N=108) had Ph- disease. Of Ph- pts, 27% (N=29) had Ph-like disease.
Most R/R-treated pts did not receive blina (N=122; 76%), inotuzumab (N=152; 94%), or stem cell transplant (SCT; N=138; 86%) in the frontline setting. In the R/R setting, 62 pts received blina (39%), 46 inotuzumab (29%), 29 SCT (18%), and 8 CAR-T (5%) at any point after R/R diagnosis (cohorts not mutually exclusive). Among R/R blina and inotuzumab-treated pts, 52% (N=32) and 57% (N=26) were treated in an academic setting, respectively. Among 53 R/R Ph+ pts, 40 (76%) received a TKI. Of 161 R/R treated pts, 128 (80%) had achieved a CR in the frontline setting. Of those who had achieved a frontline CR, 36 (28%) had documented MRD negativity after documented CR, and 36 (28%) were MRD positive. The remaining 56 pts (44%) who had achieved frontline CR did not have documented MRD testing. Following R/R tx initiation and over a median follow-up of 7.8 mos (IQR: 4.3, 21.8), 45% (N=73) of pts were still alive at data cutoff, and 55% (N=88) had a date of death.
Median rwEFS and rwOS overall from R/R tx initiation was 6.4 (95% CI: 5.1, 7.1) and 12.8 mos (95% CI: 10.4, 20.5), respectively. Median rwOS among R/R Ph+ pts (N=53) was 15.6 mos (95% CI: 12.7, Not Reached (NR)). Median rwOS among R/R Ph- pts (N=108) was 10.7 mos (95% CI: 7.1, 16.0). Median rwEFS and rwOS among Ph-like pts (N=29) was 6.5 (95% CI: 3.6, 11.7) and 12.8 mos (95% CI: 5.2, NR), respectively. Among pts treated with blina in the R/R setting (N=62), median rwEFS and rwOS were 7.5 (95% CI: 6.7, 23.9) and 21.9 mos (95% CI: 11.4, NR), respectively. Median rwEFS and rwOS among pts treated with inotuzumab in the R/R setting (N=46) were 6.7 (95% CI: 4.3, 12.0) and 12.7 mos (95% CI: 7.3, 16.8), respectively.
Conclusion: Rw outcomes for pts with R/R B-ALL who received targeted agents are worse than those observed in clinical trials, and access to some novel tx (e.g., CAR-T) remains limited. Our study highlights an unmet need for novel agents that can improve clinical outcomes for pts with R/R B-ALL.
DISCLOSURES
Enrico De Nigris, MSc: MSD (UK) Limited - Current equity holder in publicly-traded company; MSD (UK) Limited - Current Employment